Reported Earlier, Ascendis Pharma To Present New Infant Achondroplasia Trial Data At ESPE 2026
Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology
Ascendis Pharma will show new results from a medicine it's testing to help babies with a bone-growth condition. When companies share research results at big doctor meetings, it helps people understand if their treatments are working well.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.